Ibc Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.10 M
as on 30-07-2024
- Paid Up Capital ₹ 0.44 M
as on 30-07-2024
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 247.57%
(FY 2023)
- Profit 168.88%
(FY 2023)
- Ebitda 232.61%
(FY 2023)
- Net Worth 37.17%
(FY 2023)
- Total Assets 12.16%
(FY 2023)
About Ibc Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 M and a paid-up capital of Rs 0.44 M, as per Ministry of Corporate Affairs (MCA) records.
Shubham Mishra, Kranthikiran Siddappa, Rajeev Kabbur, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239MH2011PTC215791
- Company No.
215791
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Apr 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ibc Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Kabbur  | Director | 29-Nov-2017 | Current |
| Shubham Mishra | Director | 05-Apr-2011 | Current |
| Kranthikiran Siddappa | Director | 29-Nov-2017 | Current |
| Rajeev Kabbur | Director | 05-Apr-2011 | Current |
| Ravindranath Talasila | Director | 29-Nov-2017 | Current |
Financial Performance of Ibc Pharmaceuticals.
Ibc Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 247.57% increase. The company also saw a substantial improvement in profitability, with a 168.88% increase in profit. The company's net worth Soared by an impressive increase of 37.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ibc Pharmaceuticals?
In 2023, Ibc Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brio Pharma Technologies Private LimitedActive 19 years 1 monthShubham Mishra and Deepak Kabbur are mutual person
Brio Packaging Private LimitedActive 11 years 8 monthsShubham Mishra and Deepak Kabbur are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ibc Pharmaceuticals?
Unlock and access historical data on people associated with Ibc Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ibc Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ibc Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
